Pilot Projects Program

摘要 临床和翻译基础设施网络(CTR-IN)是由7个州的13个机构组成的合作伙伴关系 发展一种协作的多学科临床和转化性健康差异研究文化 并在整个西方思想机构中积极影响我们社区的健康。支持CTR试点 项目是CTR-IN的主要活动之一。CTR-IN试点项目计划(CP3，以前称为CTPG [临床和转化型试点助学金])开发了经过良好测试的征集、功绩审查和 对试点赠款的监督。CTR-IN试点获奖者的成功是通过密切整合实现的 为调查人员提供CP3资金，并由以下机构提供生物统计、指导和专业发展支持 互补的CTR-IN核心。为了进一步发展成功的CP3，我们已经制定了我们的战略，专注于 关于健康差距的研究，我们已经制定了支持多站点合作的创新战略 以及建立多学科的CTR团队。国家方案三的筹资战略将加强目前的CTR能力。 在该地区的几条战线上。首先，在过去的5年里，拥有CTR-IN飞行员的调查人员比例很高 赠款支持成功地获得了有竞争力的外部资金，产生了正的投资回报 这一数字将继续增长。我们会继续与政府部门紧密合作，推动这个目标 新的社区参与和外展(CEO)核心，以确定高危人群和健康差距 我们社区的担忧。其次，跨网站合作将建立必要的基础设施来竞争 在全国范围内进行多点临床试验和相关研究。我们最近对多站点协作试点的支持 项目既展示了研究人员对此类项目的需求，也展示了 启动这些更复杂的项目。最后，支持连接临床前和临床的伙伴关系 研究将加快向患者和社区交付解决方案。我们合作院校的教职员工 包括由IDEA支持基础科学、临床前研究人员(例如INBRE、Cobre)和 临床研究人员，为建立团队和利用核心资源推进创造机会 为患者和社区带来更大利益的研究。总之，这些战略和预期结果 将对我们社区的健康产生重要影响。

Summary The Clinical and Translational Infrastructure Network (CTR-IN) is a partnership of 13 institutions across 7 states to develop a culture of collaborative multidisciplinary clinical and translational health disparities research within and across western IDeA institutions to positively impact health in our communities. Support for CTR pilot projects is one of the key CTR-IN activities. The CTR-IN Pilot Projects Program (CP3, formerly known as CTPG [Clinical and Translational Pilot Grants]) has developed well-tested strategies for solicitation, merit review, and oversight of pilot grants. The success of CTR-IN pilot awardees is made possible through the close integration of CP3 funding for investigators with the biostatistical, mentorship and professional development support from the complementary CTR-IN Cores. To further grow the successful CP3, we have evolved our strategy to focus on health disparities research, and we have developed innovative strategies to support multisite collaborations and the building of multidisciplinary CTR teams. The CP3 funding strategies will enhance current CTR capacity in the region on several fronts. First, over the past 5 years a high proportion of investigators with CTR-IN pilot grant support have successfully obtained competitive extramural funding, yielding a positive return on investment that will continue to grow. We will continue to advance this objective by working in close collaboration with the new Community Engagement and Outreach (CEO) Core to identify populations at risk and health disparities of concern in our communities. Second, partnering across sites will build the necessary infrastructure to compete nationally for multisite clinical trials and related research. Our recent support of multisite collaborative pilot projects demonstrates both the demand for such projects among researchers and the proof of concept for initiating these more complex projects. Finally, supporting partnerships that bridge preclinical and clinical research will accelerate the delivery of solutions to patients and communities. Faculty at our partner institutions include a broad cohort of IDeA-supported basic science, preclinical investigators (e.g., INBRE, COBRE) and clinical investigators, yielding opportunities for building teams and leveraging core resources to advance research for greater benefit to patients and communities. Altogether, these strategies and anticipated outcomes will have an important impact on health in our communities.